A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma

NCT06841185 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

656

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

DRUG: HLX13
DRUG: US-sourced YERVOY®
DRUG: EU-sourced YERVOY®

Sponsor

Shanghai Henlius Biotech